文献速递类风湿关节炎

早期类风湿关节炎中甲氨蝶呤治疗持续性的全基因组研究

Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在3902例首次使用甲氨蝶呤单药治疗的瑞典早期类风湿关节炎患者中开展全基因组关联研究,未发现单个SNP与1年或3年治疗持续性达到全基因组显著性;类风湿关节炎多基因风险评分与持续性无显著关联,但持续性遗传力在1年为0.45、3年为0.14。

要点

  • 未发现单个SNP与甲氨蝶呤1年或3年治疗持续性达到全基因组显著性(P<5×10⁻⁸)。
  • 类风湿关节炎多基因风险评分与1年持续性RR=0.98(0.96-1.01)、3年RR=0.96(0.93-1.00)均无显著关联。
  • 甲氨蝶呤单药治疗持续性在遗传易感性更高的患者中更低(依据多基因风险评分)。

核心结论

  • 尽管是迄今规模最大的甲氨蝶呤治疗结局全基因组关联研究,未检测到全基因组显著关联。
  • 观察到的遗传力中等,结合提示性关联位点的广泛分布,表明遗传影响呈多基因性质。
  • 依据多基因风险评分,类风湿关节炎遗传易感性更高的患者甲氨蝶呤单药治疗持续性更低。

研究设计与样本

  • 在3902例以甲氨蝶呤作为首次-ever改善病情抗风湿药单药治疗的瑞典早期类风湿关节炎患者中开展全基因组关联研究。
  • 结局为短期和长期甲氨蝶呤治疗持续性,分别定义为1年和3年时仍使用甲氨蝶呤且未加用其他改善病情抗风湿药。
  • 遗传预测因子包括单个SNP及基于与类风湿关节炎风险相关SNP计算的多基因风险评分,并按类风湿关节炎血清状态分层估计持续性的SNP遗传力。

主要发现

  • 无论1年还是3年持续性,均无单个SNP达到全基因组显著性(P<5×10⁻⁸)。
  • 类风湿关节炎多基因风险评分与1年甲氨蝶呤治疗持续性无显著关联,RR=0.98(0.96-1.01)。
  • 类风湿关节炎多基因风险评分与3年甲氨蝶呤治疗持续性无显著关联,RR=0.96(0.93-1.00)。
  • 甲氨蝶呤治疗持续性遗传力估计值在1年为0.45(0.15-0.75),在3年为0.14(0-0.40)。
  • 血清阳性类风湿关节炎的结果与总体分析相当,而血清阴性类风湿关节炎中遗传力估计值及多基因风险评分RR均减弱趋近于零。

关键数值与推荐

  • 全基因组显著性阈值定义为P<5×10⁻⁸。
  • 1年持续性多基因风险评分RR=0.98(0.96-1.01)。
  • 3年持续性多基因风险评分RR=0.96(0.93-1.00)。
  • 1年持续性遗传力=0.45(0.15-0.75),3年持续性遗传力=0.14(0-0.40)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the influence of genetic factors on persistence with treatment of early RA with MTX monotherapy. METHODS: We conducted a genome-wide association study (GWAS) in a sample of 3902 Swedish early-RA patients initiating MTX in DMARD monotherapy as their first-ever DMARD. The outcome, short- and long-term MTX treatment persistence, was defined as remaining on MTX at 1 and at 3 years, respectively, with no additional DMARDs added. As genetic predictors, we investigated individual SNPs, and then calculated a polygenic risk score (PRS) based on SNPs associated with RA risk. The SNP-based heritability of persistence was estimated overall and by RA serostatus. RESULTS: No individual SNP reached genome-wide significance (P < 5 × 10-8), either for persistence at 1 year or at 3 years. The RA PRS was not significantly associated with MTX treatment persistence at 1 year [relative risk (RR) = 0.98 (0.96-1.01)] or at 3 years [RR = 0.96 (0.93-1.00)]. The heritability of MTX treatment persistence was estimated to be 0.45 (0.15-0.75) at 1 year and 0.14 (0-0.40) at 3 years. The results in seropositive RA were comparable with those in the analysis of RA overall, while heritability estimates and PRS RRs were attenuated towards the null in seronegative RA. CONCLUSION: Despite being the largest GWAS on an MTX treatment outcome to date, no genome-wide significant associations were detected. The modest heritability observed, coupled with the broad spread of suggestively associated loci, indicate that genetic influence is of polygenic nature. Nevertheless, MTX monotherapy persistence was lower in patients with a greater genetic disposition, per the PRS, towards RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sysojev AÖ, Saevarsdottir S, Diaz-Gallo LM, et al. Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37326842. doi:10.1093/rheumatology/kead301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。